The PennZone

  • Home
  • Business
  • Health
  • Braces
  • Sports
  • Dental Implants
  • Lacrosse
  • Legal
  • Technology

Blackrock Neurotech and University of Pittsburgh to Expand Reach of Brain-Computer Interface Trials with In-Home System
The PennZone/10187978

Trending...
  • Pennsylvania: Gov. Wolf Reacts to Dismantling of Roe v. Wade: "Elections Matter"
  • Is Woody Biomass Fuel Making a Comeback?
  • Citadel Credit Union's Business Banking Team Ready for August Launch
A compact, remote BCI system will enable expansion of in-home study sessions, extending the geographic reach and number of individuals that can participate in BCI research.

SALT LAKE CITY, June 21, 2022 /PRNewswire/ -- Brain-computer interface (BCI) trials may soon be more accessible to a greater population of candidates living with paralysis, per a new partnership agreement between Blackrock Neurotech, a leader in implantable brain technology, and the University of Pittsburgh's Rehab Neural Engineering Labs (Pitt RNEL). The agreement sets the stage for Pitt RNEL to scale future brain-computer interface (BCI) studies, enabling more people with remote BCI systems to participate in study sessions from their homes. Pitt RNEL is also creating a process to expand and improve participant recruitment, both remote and on-site, ultimately enabling larger studies with greater numbers of volunteers.

Since 2004, implantable BCIs have offered people with spinal cord injuries and other neurological disorders the potential to restore abilities. These BCI systems, comprised of miniaturized electronics, hardware, and machine learning software, decode and translate brain signals into digital commands, providing people with paralysis the ability to control external devices such as computer cursors or robotic arms.

Pitt was among the first research centers to implant Blackrock's BCI in human participants and has since conducted pioneering trials on a range of BCI applications, including complex control of robotic limbs and restoring sensory feedback using electrical stimulation of the brain. However, participation in Pitt's clinical trials has, up to now, largely been limited to people living within driving distance of the institution.

"Typical experiments require participants to come into our lab facilities on a regular basis, which is a successful model that will continue to be essential in pushing BCI science forward for years to come," said Michael Boninger, professor of physical medicine and rehabilitation and investigator in the Rehab Neural Engineering Labs at Pitt. "However, home testing has become an important supplement to lab testing whereby we enlist study staff to attend sessions and transport parts of the lab equipment to the participant's home to conduct testing. With this new initiative, we will develop a miniaturized and streamlined BCI system designed to work in people's homes, while replicating the potential for complex lab-based experiments."

More on The PennZone
  • High-Quality and Affordable Braces in Springfield Available from Exeter Orthodontics
  • Southampton Dentures from DICE Dental Start at Only $499
  • Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
  • Kelusky, Dietrich, Dawick, Gregoire, Lyle & Jeremy Thompson Nab Honors As NLL Opens Awards
  • New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject

Under this newly funded collaboration, BCI sessions using this new system will occur at the homes of people participating in the study, demonstrating that BCI research can extend outside of the greater Pittsburgh area. By reducing the challenge of study-related travel, researchers can test a broader population of participants and collect more diverse safety and efficacy data. Importantly, these in-home BCI trials are distinct from other at-home trials Pitt has conducted, where portable systems have been used independently by participants for limited testing and recreational purposes.

The Pitt RNEL group has previously shown that a portable BCI system could be successfully used at home to perform a variety of tasks by imagining the movement of a mouse cursor on the system's integrated monitor, ranging from playing computer games and typing sentences to creating digital art.

"I first started using the portable system on my own in the summer of 2020, when COVID shut down testing at the lab," said study participant Nathan Copeland. "I think in-home devices are the next essential step for getting BCI technology into the brains of the people that could have their lives improved by it. Whether it's to draw cute cats, play video games, or as a primary tool for communication, the capability of using the system in the real world beyond the confines of a lab building will start changing lives and how people think about BCI."

The expanded trials and compact system are an important step in Blackrock's efforts to make the first BCI platform commercially available to people with paralysis. The technology, which has been chronically implanted in humans since 2004, has until now only been available to patients through research studies – but Blackrock believes it is ready for real-world use.

"At a neuroscience conference a few years ago, three participants in clinical trials of Blackrock devices sat on a panel and expressed a consensus that our technology addressed immediate needs in their lives," said Marcus Gerhardt, CEO and co-founder of Blackrock. "Through this expansion of our partnership with Pitt, we will be able to connect with and learn from larger patient populations, with the guiding vision of making the technology available to as many patients as possible."

More on The PennZone
  • Pennsylvania: Gov. Wolf Announces Federal Transit Administration Grant to Expand Access to Transportation Assistance Programs
  • Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
  • Global Tax Management Launches GTM Training Institute to Address Tax Talent Gap
  • Fulton Bank to Eliminate Consumer Non-Sufficient Funds and Extended Overdraft Fees
  • Health Advisory: Protecting Yourself and Others from Monkeypox

More information on the remote trials and recruitment efforts at the University of Pittsburgh can be found here.

About Blackrock Neurotech

Blackrock Neurotech is dedicated to the clinical translation of brain-computer interface (BCI) technology. Blackrock, founded in 2008, is the world's leading platform company for BCI technology and the development of implantable solutions that improve human lives. Blackrock's precision electrode technology is at the core of many worldwide innovations in BCI, enabling dozens of early users (known as "BCI Pioneers") to SeeAgain, HearAgain, MoveAgain and more. For more information, visit https://blackrockneurotech.com/

About the University of Pittsburgh Schools of the Health Sciences

The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences, and Public Health. The schools serve as the academic partner to UPMC. Together, their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease, and participate in the delivery of outstanding patient care. Pitt has ranked among the top recipients of funding from the National Institutes of Health since 1998. For additional information about Pitt Health Sciences, please visit https://www.health.pitt.edu/.

Media contact:
Lightspeed PR/M for Blackrock
[email protected]

SOURCE Blackrock Neurotech
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME
  • SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
  • Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
  • Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
  • Pennsylvania: Gov. Wolf Applauds President Biden's Signing of First Comprehensive Gun Violence Package in Decades
  • Direct Purchaser Plaintiffs Announce Settlements in In Re Generic Pharmaceutical Pricing Antitrust Litigation.
  • Pennsylvania Commissions Condemn Supreme Court Decision, Remain Committed to Protecting the Right to Choose
  • Pennsylvania: Gov. Wolf Shares Relief with Congressional Passage of Bipartisan Safer Communities Act, Urges Continued Momentum for Safer Communities
  • Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
  • Ismail Sirdah' Guide To Landing Event Sponsorships
  • INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Yext, Inc. (YEXT) Investors
  • Pennsylvania: Gov. Wolf Reacts to Dismantling of Roe v. Wade: "Elections Matter"
  • Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
  • The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
  • iTech offers 60-days free trial on expEDIum Medical Billing® product
  • Pennsylvania: Gov. Wolf Commends Bipartisan Effort to Combat Surging Gun Violence, Eager for U.S. House to Send Bipartisan Safer Communities Act to President Biden's Desk
  • Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
  • On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
  • Citadel Credit Union's Business Banking Team Ready for August Launch
  • Is Woody Biomass Fuel Making a Comeback?

Popular on PennZone

  • Company Changes YouTube Channel Name to Steve Tristan's Best
  • NetDiligence Announces Recipients of 2022 Toby Merrill Awards
  • G. ENTERTAINMENT proudly presents Indianapolis' Inaugural Juneteenth Celebration Weekend Kick-Off with the "What the Funk" Concert
  • Terrorism is again on the rise warnings in new TERROR STRIKES book release
  • Houwzer’s RiseUp Fund To Host Timely Discussion on Affordable Housing at Drexel University
  • Resco Products Announces Price Increase Effective June 1st
  • Wesco Declares Quarterly Dividend on Preferred Stock
  • InventHelp Inventor Develops Modified Spout for Bathtubs (TNO-110)
  • Massage Therapy Makes The Perfect Gift For The Person Who Has Everything
  • Linksys and Axiros Collaborate to Provide Whole Home Coverage and Deep Insight into WiFi Network

Similar on PennZone

  • Alcoa Schedules Second Quarter 2022 Earnings Release and Conference Call
  • MULLEN AUTOMOTIVE, INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against Mullen Automotive, Inc. (NASDAQ: MULN, NETE); Lead Plaintiff Deadline is July 5, 2022
  • Global Tax Management Launches GTM Training Institute to Address Tax Talent Gap
  • Fulton Bank to Eliminate Consumer Non-Sufficient Funds and Extended Overdraft Fees
  • The Jefferson Institute of Bioprocessing to Bring Biologics Training to Budd Bioworks
  • Kano Laboratories, Makers of Kroil, Announces Refreshed Branding for Extended Line of Industrial Product Solutions
  • SIFCO ASC launches new game changing plating system with dripless technology
  • BetMGM Expands BetQL Network Relationship as the Presenting Sportsbook Partner
  • Prolific Author Tam R. Luc Celebrates Positive Title IX Achievements and Pushes Businesswomen to the Next Level with Boss Up Summit
  • BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us